Table 3. A comparison of various studies on frequency of PDL1 in breast cancers from different parts of India .

PDL1: Programmed death receptor ligand 1; TNBC: Triple-negative breast cancer

Study	Present Study	Bhardwaj et al. [24]	Ghosh et al. [23]	Sharma et al. [22]	Mehan et al. [21]	Punhani et al [26].
1. Region of India	South India	South India	East India	North India	North India	North India
2. Year of publication	-	2019	2021	2021	2022	2023
3. Number of patients	120	132	107	40	103	150
a. Metastatic disease	120	NA	Nil	20	14	NA
b. Non-metastatic disease	-	NA	107	-	89	NA
4. Molecular classification	TNBC	All including TNBC	TNBC	TNBC	All subtypes	All subtypes
5. Median age	46	NA	Ventana SP 142	40 to 60	51	NA
6. Platform used	22C3	RTqPCR	-	-	SP 263	NA
7. PDL1 Positivity	31.66% in tumor and  immune cells	52% in immune cells 13% in tumor cells amongst TNBC	NA	32.5% in tumor cells	59.2% in Immune cells 37.9% in tumor cells	14.67